Cardinal Health Recalls Webcol Alcohol Prep Pads Due to Microbial Contamination

Cardinal Health issued a voluntary nationwide recall of Webcol Alcohol Prep Pads on January 17, 2025, after identifying contamination with Paenibacillus phoenicis, a gram-positive bacterium. The recall affects wholesale distributors, hospitals, and healthcare facilities that distributed or stocked these products between May 2023 and December 2024. Immunocompromised patients face the highest risk from exposure to contaminated prep pads used for skin antisepsis before injections or procedures.

Regulatory Framework for Medical Device Recalls

The FDA classifies this action as a Class II recall under 21 CFR Part 7, Subpart C. Class II recalls address situations where use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. The FDA does not mandate Class II recalls—Cardinal Health initiated this action voluntarily after internal quality testing detected the contaminant.

Medical device recalls follow pharmaceutical product recall procedures established under the Federal Food, Drug, and Cosmetic Act, Section 518(e). Wholesale drug distributors handling recalled devices must comply with recall notification requirements even when the manufacturer initiates the action directly. The FDA's Medical Device Recall Guidance (updated 2019) requires distributors to maintain documentation of recall communications sent to downstream customers and to verify product removal from active inventory.

Recall Scope and Product Details

The recall covers three specific lot numbers of Webcol Alcohol Prep Pads distributed in medium and large sizes:

• Lot 24E06BB (Medium) — Expiration: May 2026
• Lot 24L16BB (Large) — Expiration: December 2026
• Lot 24L28BA (Large) — Expiration: December 2026

Cardinal Health distributed these lots nationwide through its wholesale distribution network. The company has not disclosed the total unit count affected, but Webcol prep pads are standard inventory items at acute care hospitals, outpatient clinics, dialysis centers, and home healthcare suppliers.

Paenibacillus phoenicis is an opportunistic pathogen. In healthy individuals, skin exposure rarely causes infection. In immunocompromised patients—including chemotherapy recipients, transplant patients, and individuals with chronic wounds—the bacterium can cause localized skin infections or, in rare cases, systemic bacteremia if introduced during invasive procedures. The FDA has received no confirmed adverse event reports related to this contamination as of the recall announcement date.

Wholesale Distributor Recall Responsibilities

Wholesale drug distributors must execute medical device recall protocol consistent with their internal Standard Operating Procedures (SOPs) for product withdrawals. Key operational steps include:

1. Quarantine affected inventory — All three lot numbers must be removed from distribution-ready stock and segregated pending return or destruction instructions.
2. Customer notification — Distributors must send recall notices to all healthcare facilities that received affected lots, documenting the date and method of notification.
3. Return coordination — Cardinal Health provided a dedicated recall hotline (1-800-234-8097) and online portal for processing returns. Distributors must track which customers have acknowledged the recall and confirmed product removal.
4. Documentation retention — FDA guidance recommends retaining recall records for two years beyond the product expiration date. For these lots, that extends through December 2028.

Distributors holding NABP Verified-Accredited Wholesale Distributors (VAWD) accreditation must demonstrate compliance with NABP Model Rules Section 5.8, which requires written recall procedures and quarterly testing of recall effectiveness. This recall provides a real-world test case for those procedures.

The recall does not affect Cardinal Health's FDA registration status (FEI 3002806360) or state wholesale drug distributor licenses. The company maintains active licensure in 48 states with an average cardinal health compliance score of 75/100 in ColdChainCheck's directory, reflecting no prior recalls in the current tracking period.

What ColdChainCheck Data Shows

ColdChainCheck tracks 73 entities with recalls on record out of 1,275 wholesale distributors, 3PLs, and cold chain providers in the directory. This Cardinal Health recall represents a Class II medical device action—a compliance signal that affects Cardinal Health's ColdChainCheck profile but does not trigger an automatic score reduction under the current methodology, which weighs drug product recalls more heavily than medical device or supply recalls.

Cardinal Health operates one of the largest pharmaceutical distribution networks in the United States, meaning this recall's downstream impact extends beyond the company's direct compliance posture. Healthcare facilities and specialty pharmacies sourcing alcohol prep pads through intermediary distributors should verify whether their suppliers received affected lots. The average compliance score across all tracked entities is 51/100, placing most distributors in the "Fair" tier (919 entities). Distributors in this tier may lack documented recall response procedures that meet NABP Model Rules Section 5.8 requirements.

Only 63 entities in ColdChainCheck's directory hold NABP VAWD accreditation, which requires quarterly recall procedure testing. Healthcare procurement teams working with non-accredited distributors should independently verify that those trading partners:

• Maintain current written recall SOPs accessible to warehouse and logistics staff
• Document customer notification methods (email, phone, portal, or certified mail)
• Track acknowledgment rates from downstream healthcare facilities
• Retain recall records for the required retention period (minimum two years post-expiration)

Practical Guidance for QA and Procurement Teams

• Check your distributor's profile — Use the ColdChainCheck directory to verify whether your wholesale distributor holds active FDA registration and state licenses. Entities without current registration may not receive direct FDA recall notifications.
• Verify lot-specific inventory — Contact your primary distributor to confirm whether your facility received Webcol lots 24E06BB, 24L16BB, or 24L28BA. Request written confirmation of product removal if applicable.
• Document the recall response — For auditors and state board inspections, maintain timestamped records showing when you received recall notification, how you verified inventory, and what disposition occurred (return, destruction, or confirmed non-receipt).
• Review backup supplier compliance — If this recall disrupts alcohol prep pad supply, secondary suppliers should meet minimum compliance thresholds: active state licensure, FDA registration, and documented recall procedures. Filter the directory by state to identify licensed alternatives in your jurisdiction.

ColdChainCheck tracks FDA enforcement actions, state board disciplinary records, and product recalls as part of the compliance scoring methodology. For ongoing coverage of pharmaceutical product recall procedures and wholesale drug distributor recall responsibilities, see the compliance guides section.

Disclaimer: This article is for informational purposes only and does not constitute legal or regulatory advice. Verify all compliance requirements with the FDA, relevant state boards of pharmacy, and qualified legal counsel.